Disease: Psychotic disorders

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine

mycolabadmin

This review examines how psychedelic drugs like ketamine, MDMA, and psilocybin could offer new hope for people with PTSD by working on the brain differently than current medications. These compounds work quickly and help the brain form new neural connections that can help people process traumatic memories more effectively. When combined with therapy, these drugs show promise in reducing PTSD symptoms faster and more effectively than traditional antidepressants. The review also explains how doctors could use personalized medicine approaches using brain scans and genetic testing to determine which treatment would work best for each individual patient.

Read More »

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia

mycolabadmin

Schizophrenia involves excessive loss of connections between brain cells in areas responsible for emotion and thinking, leading to negative symptoms and cognitive problems. Research shows that small doses of psychedelics like psilocybin can promote the growth of new brain connections and reduce inflammation. The authors suggest that microdosing psychedelics alongside standard treatments might help restore these lost connections and improve symptoms that don’t respond well to current medications.

Read More »

Psychedelics and the treatment of eating disorders: considerations for future research and practice

mycolabadmin

As researchers explore using psychedelic drugs like psilocybin to treat eating disorders, this article outlines important safety considerations and ethical guidelines needed before widespread use. While some early trials show promise, significant concerns exist including physiological risks (heart problems, nausea), psychological challenges, potential for therapist misconduct, and medication interactions. The authors recommend rigorous research designs, better inclusion of diverse populations, and careful integration of psychedelics with proven eating disorder treatments.

Read More »

Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies

mycolabadmin

This research review examined whether people with schizophrenia can safely participate in psychedelic-assisted therapy treatments. Researchers analyzed 131 studies and found that psychedelics rarely cause new psychosis in the general population (0.002%), though the risk is slightly higher in people with existing schizophrenia (3.8%). While the immediate risk appears manageable, about 13% of people who develop psychosis from psychedelics go on to develop schizophrenia, suggesting caution is still needed.

Read More »
Scroll to Top